Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 146 results for multiple sclerosis

  1. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

    Clinical guideline
    Last updated
    22 September 2020
    View recommendations

    Sections for CG173

  2. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

    Technology appraisal guidance
    Topic selection

  3. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...

    Research recommendation
    Published
    9 June 2015

  4. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  5. Past appeals and decisions

    disease - riluzole 4 January 2001 TA129 Multiple myeloma - Bortezomib 8 February 2007 TA228 Multiple myeloma (first line) -...

  6. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    NICE visualisation of treatment options incorporating technology appraisals: interim process guide

  7. Stereotactic radiosurgery for trigeminal neuralgia (IPG715)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

    Interventional procedures guidance
    Published
    2 February 2022
    View recommendations

    Sections for IPG715

  8. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  9. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  10. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

    Technology appraisal guidance
    Discontinued

  11. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  12. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  13. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

    Technology appraisal guidance
    Discontinued

  14. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    (licensed product in UK: Sativex) for treating spasticity in people with multiple sclerosis. There were reductions in some measures of...

    Research recommendation
    Published
    10 February 2020

  15. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

    Interventional procedures guidance
    Published
    27 October 2010
    View recommendations

    Sections for IPG362